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Rhabdomyosarcoma (RMS) is the most common
soft tissue sarcoma in children, whereas undifferenti-
ated pleomorphic sarcoma (UPS) is one of the most
common soft tissue sarcomas diagnosed in adults.
To investigate the myogenic cell(s) of origin of these
sarcomas, we used Pax7-CreER and MyoD-CreER
mice to transform Pax7+ and MyoD+ myogenic
progenitors by expressing oncogenic KrasG12D and
deleting Trp53 in vivo. Pax7-CreER mice developed
RMS and UPS, whereas MyoD-CreER mice devel-
oped UPS. Using gene set enrichment analysis,
RMS and UPS each clustered specifically within their
human counterparts. These results suggest that RMS
and UPS have distinct and overlapping cells of origin
within the muscle lineage. Taking them together,
we have established mouse models of soft tissue
sarcoma from muscle stem and progenitor cells.INTRODUCTION
Soft tissue sarcomas account for approximately 10%of all newly
diagnosed cancers in children, adolescents, and young adults;
more than half of these tumors are rhabdomyosarcoma (RMS)
(Arndt and Crist, 1999; Meyer and Spunt, 2004). RMS is charac-
terized by the presence of rhabdomyoblasts and immunohisto-
chemical (IHC) staining for myogenic transcription factors such
as MyoD and Myogenin (Morotti et al., 2006). Although patientsCewith RMS who present with local disease are frequently cured,
5 year survival rates for children with metastatic disease are
less than 25% (Arndt and Crist, 1999). By contrast, undifferenti-
ated pleomorphic sarcoma (UPS) represents one of the most
common histological subtypes of soft tissue sarcoma diagnosed
in adults. Characterized by a lack of tissue-specific differentia-
tion, it is a diagnosis of exclusion. However, with careful exami-
nation, a subset of these tumors has been shown to express
myogenic markers (Fletcher et al., 2001). Therefore, UPS may
have multiple cells of origin with a convergent undifferentiated
histological endpoint. Because approximately one-third of pa-
tients with RMS and UPS die from their disease, new therapies
are needed for these cancers. Moreover, because contemporary
treatment for these sarcomas often includes radiation and/or
chemotherapy, survivors are at risk for second malignancies
and other late effects of treatment. Thus, more targeted treat-
ments for RMS and UPS with fewer side effects are needed.
Although the cell(s) of origin for RMS and UPS are not yet fully
defined, candidates include the numerous myogenic cell types
that are present in normal muscle tissue (Hettmer and Wagers,
2010; Linardic et al., 2005; Rubin et al., 2011). These unique
myogenic cell populations can be identified by the expression
of specific transcription factors. For example, satellite cells,
which include the muscle stem cells, express Pax7 (Kuang
et al., 2006). The satellite cell population is heterogeneous, con-
sisting of quiescent Pax7+MyoD stem cells and another sub-
population that expresses MyoD (Buckingham and Relaix,
2007; Sacco et al., 2008). These two subpopulations have
different capacities for self-renewal, underscoring functional het-
erogeneity within the satellite cell compartment. Upon injury or
exercise, satellite cells become activated, express Pax7 andll Reports 5, 933–940, November 27, 2013 ª2013 The Authors 933
MyoD, and differentiate into myoblasts, which function as transit
amplifying cells (Sabourin et al., 1999).
Because human embryonal RMS (eRMS) frequently ex-
presses both Pax7 and MyoD (Tiffin et al., 2003), it seems
reasonable that a Pax7 or MyoD-expressing myogenic progeni-
tor would be a candidate cell of origin in eRMS. However,
a recent study reported that differentiating myoblasts that ex-
press the terminal differentiation marker Myf6 give rise to
eRMS. Using Myf6-Cre;Trp53Fl/Fl mice, the tumor suppressor
Trp53 was ablated in Myf6+ cells throughout development, and
these mice preferentially gave rise to eRMS, whereas a Pax7-
CreER;Trp53Fl/Fl mouse developed UPS (Rubin et al., 2011).
Here, we used mice that express tamoxifen-inducible CreER
from either the endogenous Pax7 orMyoD promoters to simulta-
neously drive expression of oncogenic Kras and delete Trp53.
We found that Pax7+ satellite cells are cells of origin for RMS
and UPS, whereas Pax7+MyoD+ myogenic progenitors are cells
of origin for UPS, which suggests that muscle stem cells are a
cell of origin for RMS.
RESULTS
Transformation of Pax7+ Myogenic Progenitors In Vivo
Gives Rise to a Spectrum of Myogenic Sarcomas
We have previously utilized genetically engineered mice carrying
conditional oncogenicKrasG12D andTrp53 knockout alleles (LSL-
KrasG12D/+;Trp53Fl/Fl) to generate a spatially and temporally
restricted mouse model of soft tissue sarcoma (Kirsch et al.,
2007). To restrictmutations ofKras and Trp53 to Pax7+myogenic
progenitors, we crossedPax7-CreERT2mice (Lepper et al., 2009)
into the LSL-KrasG12D/+;Trp53Fl/Fl model to generate Pax7CE/+;
LSL-KrasG12D/+;Trp53Fl/Fl mice, hereafter termed P7KP. We
injected greater than 6-week-old P7KP mice (n = 17) with sys-
temic tamoxifen via intraperitoneal (IP) delivery. The mice devel-
oped multiple tumors with 100% penetrance within 1–2 months
at various anatomic locations including clinically relevant sites
such as the orbit (Figure 1A). Tumors (n = 67, 3.9 tumors per
mouse on average) displayed a histological spectrum ranging
from UPS to RMS and included sarcomas that mimicked embry-
onal RMS (eRMS), pleomorphic RMS (pRMS), myogenic UPS,
and nonmyogenic UPS (Figures 1B–1I and S1A–S1N). In terms
of anatomic distribution, 37% of sarcomas appeared in the
body wall, 31% in the extremities, 23% in the head and neck,
and 9% were subcutaneous (Figure 1J). Based on hematoxylin-
and-eosin (H&E)-stainedhistological sections, 62%of the tumors
were UPS with the remainder being RMS, which were predomi-
nantly eRMS like, though some tumors had pRMS-like or rarely
aRMS-like features (Figure 1K). Although 100% of the eRMS
and 89% of the pRMS were classified as myogenic by staining
forMyoD, Pax7, orMyogenin, 74%of theUPS stained for at least
one of these myogenic markers (Figure 1L). Therefore, transfor-
mationofPax7+myogenicprogenitors in vivogives rise to aspec-
trum of sarcomas ranging from RMS to UPS.
Generation and Characterization of MyoDCE/+ Mice
Given the spectrum of sarcomas that arose in the P7KPmice, we
hypothesized that different subpopulations of Pax7+ cells give
rise to RMS and UPS because Pax7 is expressed in quiescent934 Cell Reports 5, 933–940, November 27, 2013 ª2013 The Authorssatellite cells, activated satellite cells, and myoblasts. Because
MyoD is expressed in activated satellite cells and myoblasts,
we next studied sarcoma development in mice in which CreER
is driven by MyoD. First, we generated MyoDCE/+ mice in which
CreER was knocked into the MyoD locus and expressed from
the endogenous MyoD promoter (Figures 2A and S2A–S2F). To
compare the expression of Cre in MyoDCE/+ and Pax7CE/+ mice,
we crossed these strains to the dual reporter mouse R26mTmG
(Muzumdar et al., 2007). The R26mTmG reporter expresses mem-
brane targeted tandem-Tomato in the absence of Cre. After Cre-
mediated recombination, the tandem-Tomato gene is deleted
and membrane targeted GFP is expressed constitutively in the
cell and its descendants. We injected Pax7CE/+;R26mTmG/+ and
MyoDCE/+;R26mTmG/+ mice (greater than 6 weeks of age) with IP
tamoxifen to determine if there was a difference in membrane
GFP (and thus Cre) expression in skeletal muscle cells by flow
cytometry. We observed that the Pax7CE/+;R26mTmG/+ muscle
contained significantly more GFP+ cells than the MyoDCE/+;
R26mTmG/+ muscle (Figure 2B). This result is consistent with
Pax7 expression in adult muscle satellite cells (Kuang et al.,
2006; Lepper et al., 2009; Sacco et al., 2008), because MyoD
expression only becomes prominent in satellite cells after activa-
tion (Cornelison et al., 2000; Zammit et al., 2002).
To further explore expression of CreER in theMyoDCE/+ mice,
we isolatedmyoblasts fromMyoDCE/+mice and cocultured them
with fibroblasts shedding RCAS-GFP virus for 48 hr. The CreER
knockin allele at theMyoD promoter contains the avian retroviral
receptor tva, which is expressed downstream from an internal
ribosomal entry site (IRES) on the samemRNA as theCreER (Fig-
ure S2A). Therefore, cells that express CreER from the MyoD
promoter will also express tva and will thereby be susceptible
to RCAS-GFP infection. Figure S2F shows that because myo-
blasts from MyoDCE/+ mice can be successfully infected with
RCAS-GFP, they express the CreER-IRES-tva transcript from
the MyoD promoter (Figure S2F). Additionally, myoblasts iso-
lated fromMyoDCE/CE mice coexpress MyoD and CreER at pas-
sage 1 (Figure S2G).
To ascertain if MyoDCE/+ mice drive tamoxifen-inducible Cre
activity in differentiating myogenic progenitors in vivo, we injured
the tibialis anterior (TA) muscles of Pax7CE/+;R26mTmG/+ and
MyoDCE/+;R26mTmG/ mTmG mice to induce satellite cell activation
(Sacco et al., 2008). The TAs were injured with a single intramus-
cular (IM) injection of cardiotoxin on day 0. Then, the mice were
injected with five daily doses of IP tamoxifen beginning on day 1
(Figure 2C). The mice were euthanized on day 6, and the skeletal
muscle was collected for sectioning.We observed that, similar to
Pax7CE/+;R26mTmG/+ mice, the MyoDCE/+;R26mTmG/mTmG mice
had GFP+ regenerating myofibers at the site of injury (Figure 2C).
Taken together, these results indicate that CreER in MyoDCE/+
mice is expressed in activated MyoD+ myogenic progenitors
during muscle regeneration and/or repair.
Transformed MyoD+ Myogenic Progenitors Give Rise to
UPS
To assess the spectrum of sarcomas generated from MyoD+
cells, we crossed the MyoDCE/+ mice to LSL-KrasG12D/+;
Trp53Fl/Fl mice to generate MyoDCE/+; LSL-KrasG12D/+;Trp53Fl/Fl
mice, hereafter referred to as MDKP mice. We injected greater
Figure 1. Transforming Pax7+ Myogenic Progenitors In Vivo Generates RMS and UPS
(A) P7KP mice (n = 17) were injected with systemic tamoxifen (IP TMX) and generated tumors (n = 67) at clinically relevant anatomic locations, such as the orbit.
Median tumor-free survival was 44 days.
(B and C) eRMS displayed small round, blue cell histology with rhabdomyoblasts (arrowheads) by H&E (B) and were positive for the myogenic marker MyoD (C).
(D and E) pRMS displayed characteristic large rhabdomyoblasts (arrowheads) with spindle cell histology by H&E (D) and were positive for the myogenic marker
MyoD (E).
(F and G) Nonmyogenic UPS displayed characteristic spindle cell histology with giant cells (arrowheads) by H&E (F) but lacked MyoD expression (G).
(H and I) In contrast, myogenic UPS displayed spindle cell histology (H) but were positive for MyoD (I) (403, scale bar, 50 mm).
(J) Anatomic distribution of sarcomas generated in P7KP mice injected with IP tamoxifen.
(K) Histological distribution of sarcoma subtypes in P7KP mice injected with IP tamoxifen.
(L) Myogenic distribution in the P7KP-derived UPS sarcoma subset.
See also Figure S1.than 6-week-old MDKP mice with IP tamoxifen (Figure 3A). Like
their P7KP counterparts, MDKP mice developed tumors (n = 12)
at a variety of clinically relevant anatomic sites. Interestingly,
MDKPmice developed tumors with increased latency with ame-
dian tumor-free survival of 153 days compared to P7KP mice,
which developed tumors at a median time of 44 days (Figure 1A
versus Figure 3A). In contrast to the P7KP mice, which often
developed multiple sarcomas after IP tamoxifen, the MDKP
mice usually developed a single sarcoma after IP tamoxifen.
The increased latency and decreased number of tumors per
mouse is likely due to the small number of cells expressingCeMyoD in theMDKPmice under homeostatic conditions, because
the mice were injected at an age when there are few MyoD-
expressing cells (Chakkalakal et al., 2012; Lee et al., 2012).
Sarcomas that developed in the MDKP mice were exclusively
UPS (n = 12). Similar to the UPS in P7KPmice, the UPS in MDKP
mice could be subdivided into myogenic UPS (Figures 3B, 3C,
S3F, and S3G) and nonmyogenic UPS (Figures 3D, 3E, and
S3A–S3E). The anatomic distribution of the tumors derived
from the MDKP mice was similar to the tumors in the PK7P
mice and included the extremities, body wall, and the head
and neck region (Figure 3F). Although the histological distributionll Reports 5, 933–940, November 27, 2013 ª2013 The Authors 935
Figure 2. Characterization of MyoDCE/+
Mice
(A) Schematic of the MyoDCE/+ allele. CreER was
targeted to the endogenous MyoD locus. In addi-
tion, the avian tumor virus receptor A (tva) and
MyoD are expressed from dual internal ribosome
entry sites (IRESs).
(B) Pax7CE/+;R26mTmG/+ (n = 2) and MyoDCE/+;
R26mTmG/+ (n = 2) mice were injected (IP) with
tamoxifen (TMX) for 5 consecutive days and
sacrificed 10 days later. Pax7CE/+;R26mTmG/+ mice
contained a GFP+ satellite cell population,
whereas MyoDCE/+;R26mTmG/+ mice had no iden-
tifiable GFP+ population.
(C) Following injury with intramuscular cardiotoxin
(CTX) and five daily TMX IP injections, both
Pax7CE/+;R26mTmG/+ and MyoDCE/+;R26mTmG/mTmG
mice (n = 3) exhibited GFP+ regenerating muscle
fibers (403, scale bar, 50 mm).
See also Figure S2.of sarcomas in the MDKP model was restricted to UPS (Fig-
ure 3G), 60% stained with either MyoD or Myogenin (Figure 3H).
These results indicate that MyoD+ myogenic progenitors are a
cell of origin for both myogenic and nonmyogenic UPS.
P7KP and MDKP-Derived UPS Cluster Separately from
P7KP-Derived RMS at the Gene Expression Level and
Mimic Their Human Counterparts by Gene Set
Enrichment Analysis
To investigate if the histological spectrum of tumors from P7KP
and MDKP mice reflects underlying molecular differences, we
isolated mRNA from sarcomas derived from MDKP mice and
all three histological variants (UPS, pRMS, and eRMS) from
P7KP mice. We first compared the gene expression profiles by
principal component analysis (PCA). This unbiased approach
transforms the many correlated gene expression measurements
for each sample into a set of uncorrelated principal component
scores, while still capturing the greatest possible variation in
gene expression. We plotted all of the samples on a two-dimen-
sional plot using the principal component scores from the first
two principal components (Figure 4A). Samples that are proximal
on the plot have amore similar gene expression profile than sam-
ples that are distal from one another. When examining the first
principal component scores, we found that the P7KP-derived
eRMS-like tumors clustered separately from MDKP and P7KP-
derived UPS-like tumors (Figure 4A). As expected, MDKP-
derived tumors, which appeared to be UPS by histology,
clustered more closely with P7KP-derived UPS-like tumors
than the eRMS-like tumors when using the first principal compo-
nent scores. P7KP-derived pRMS-like tumors did not cluster
together using the first principal component scores and were
distributed evenly throughout the clusters of other subtypes,
suggesting that they do not represent a distinct subtype at the
molecular level.936 Cell Reports 5, 933–940, November 27, 2013 ª2013 The AuthorsTo further analyze the gene expression
data, we performed a second unsuper-
vised approach using hierarchical clus-tering. In good agreement with the PCA results, hierarchical
clustering demonstrated that MDKP-derived tumors tend to
cluster more closely with P7KP-derived UPS-like tumors (UPS-
like clade) compared to P7KP-derived eRMS-like and pRMS-
like tumors, which tended to cluster into a separate group
(RMS-like clade) (Figure 4B). The two UPS tumors that clustered
within the RMS-like clade stained positively for either MyoD or
Myogenin. These data further suggest that there are underlying
molecular differences between different histological subtypes
of mouse sarcomas.
To investigate whether the mouse sarcoma subtypes are
similar to specific human sarcomas at the gene expression level,
we performed gene set enrichment analysis (GSEA). GSEA is an
established method of measuring the simultaneous differential
expression of multiple genes in a gene set between two classes
(i.e., tumor types A and B). We defined a gene set comprising
genes most significantly (p < 0.0001) upregulated in P7KP
RMS (eRMS and pRMS) compared to the UPS derived from
the MDKP mice (Figures 4C and S4A). Then, we used GSEA to
test whether this gene set upregulated in the P7KP RMS tumors
could be used to distinguish between human RMS and other
human soft tissue sarcomas. Using a previously annotated
human sarcoma gene expression data set (Baird et al., 2005),
we performed GSEA for each type of sarcoma by comparing
each individual sarcoma subtype to all other sarcomas in the
data set. In good agreement with the histological data, when
the gene set comprising genes upregulated in the P7KP RMS
was applied to a human data set of multiple soft tissue sarcoma
subtypes, the P7KP-derived mouse RMS enriched in human
RMS, validating this system as a model for human RMS (Fig-
ure 4C, p = 0.002, normalized enrichment score [NES] = 1.88;
false discovery rate [FDR] = 0.024). To determine whether the
P7KP UPS and MDKP UPS sarcomas mimic human sarcoma
at the molecular level, we also generated a gene set comprising
Figure 3. Transforming MyoD+ Myogenic Progenitors In Vivo Generates UPS
(A) MDKPmice injected with IP TMX generated single tumors at clinically relevant anatomic locations, such as the proximal thigh. Median tumor-free survival was
153 days (n = 12 mice).
(B and C) MDKP-derived myogenic UPS had spindle cell histology by H&E (B) and expressed the myogenic marker MyoD (C).
(D and E) In contrast, nonmyogenic UPS maintained the classic spindle cell and pleomorphic histology (D) but lacked immunoreactivity for MyoD (E) (403, scale
bar, 50 mm), Pax7, and Myogenin (Figure S3).
(F) Anatomic distribution of sarcomas generated in MDKP mice injected with IP tamoxifen.
(G) Histological distribution of sarcomas generated in MDKP mice injected with IP tamoxifen.
(H) Distribution of myogenic staining in MDKP-derived UPS.
See also Figure S3.the genesmost significantly (p < 0.001) upregulated in themouse
UPS from P7KP and MDKP mice compared to the mouse RMS
from P7KP mice (Figures 4C and S4B). This gene set was then
applied to the human sarcoma data set. Like the gene set from
P7KP RMS sarcomas, the gene set from mouse UPS derived
from P7KP and MDKP mice enriched in its human counterpart,
validating the mouse UPS as models of human UPS (Figure 4C,
p < 0.001, NES = 1.85, FDR < 0.012).
DISCUSSION
We used the CreER-loxP system to express oncogenic Kras and
delete Trp53 specifically in Pax7-expressing or MyoD-express-
ing cells to show that both Pax7+ and MyoD+ myogenic cells
are cells of origin for bothmyogenic and nonmyogenic soft tissue
sarcomas. Sarcomas generated by Pax7+ myogenic cells dis-
played histological diversity, ranging from undifferentiated pleo-
morphic sarcoma (UPS) to differentiated eRMS, whereas MyoD+Cecells gave rise to amore restricted UPS phenotype. Furthermore,
gene sets generated by comparing mouse UPS andmouse RMS
distinguished human UPS and RMS from other soft tissue sar-
comas. Therefore, thesemouse sarcomas not only appear histo-
logically similar to human RMS and UPS, but GSEA suggests
that they phenocopy these tumors at the molecular level as well.
We used inducible Cre (CreER) alleles for cell of origin studies
of sarcomas to temporally activate gene mutations after devel-
opment. Although conditional gene manipulation using a consti-
tutive Cre allele is a powerful technique to activate or delete
genes in vivo to model cancer, unanticipated expression pat-
terns of Cre recombinase throughout development can present
challenges for pinpointing cells of origin for cancer (Heffner
et al., 2012; Lee et al., 2013; Sambasivan et al., 2013). For
example, Rubin et al. (2011) used Myf6-Cre mice to conclude
that eRMS can develop from differentiating Myf6-expressing
myoblasts, but it has recently been shown that Myf6 is not only
expressed in differentiating myoblasts and myotubes (Rubinll Reports 5, 933–940, November 27, 2013 ª2013 The Authors 937
Figure 4. Sarcomas Cluster by Histologic Subtype Using Unbiased Genomic Analysis
(A) Principal component analysis clustered P7KP-derived eRMS separately from P7KP-derived UPS and MDKP-derived tumors along the first principal
component (PC1). The second principal component (PC2) separated the UPS P7KP sarcomas from the MDKP sarcomas.
(B) Unsupervised hierarchical clustering separated the sarcomas into an RMS-like clade that includesmost P7KP-derived eRMS and pRMS and aUPS-like clade
that includes most P7KP-derived UPS and MDKP-derived tumors.
(C) GSEA demonstrates that a gene set derived from P7KP RMS (eRMS and pRMS) enrich in human RMS, whereas a gene set from P7KP-derived UPS and
MDKP sarcomas enrich in human UPS.
See also Figure S4.et al., 2011) but is also expressed in satellite cell precursors dur-
ing development (Sambasivan et al., 2013). Therefore, the cell of
origin for sarcomas from Myf6-Cre mice cannot be defined
unambiguously. Here, we used tamoxifen-activated Cre (CreER)
alleles, which can be activated after development, to show that
mutant Kras, in concert with loss of Trp53, initiates eRMS and
UPS in satellite cells, whereas UPS develops from MyoD-
expressing cells.
By comparing the sarcomas that developed in the P7KP and
MDKP mice to each other, we find that Pax7+ and MyoD+ pro-
genitor cells can give rise to distinct and overlapping myogenic
soft tissue sarcomas in vivo. Although P7KP mice generate
RMS and UPS after systemic tamoxifen administration, sys-
temic tamoxifen into MDKP mice preferentially generates UPS.938 Cell Reports 5, 933–940, November 27, 2013 ª2013 The AuthorsConsistent with this result, microarray analysis suggests that
UPS tumors from MDKP mice preferentially cluster with P7KP-
derived UPS, whereas P7KP-derived eRMS clustered in a sepa-
rate class altogether. These data imply that the transcriptional
profiles of UPS derived from P7KP and MDKP mice are more
similar to each other than they are to RMS (eRMS and pRMS)
generated in the P7KP mice; in addition, only the Pax7-express-
ing cells give rise to a spectrum of RMS, suggesting that
Pax7+MyoD+ cells are a cell of origin for UPS in vivo. These
data also raise the possibility that transformation of a myogenic
progenitor cell (not the muscle stem cell) gives rise to a more
undifferentiated sarcoma.
There are several salient features of these myogenic sarcoma
models. First, the sarcomas are initiated by mutations in genes
that are relevant to human RMS and UPS. TRP53, which is
mutated in 16.7% of human UPS (Barretina et al., 2010) and
has been reported to be mutated in human RMS (Felix et al.,
1992; Merlino and Helman, 1999; Mulligan et al., 1990; Tsumura
et al., 2006), is deleted in this model. Mutant RAS, primarily
KRAS and NRAS, is also observed in human eRMS (Martinelli
et al., 2009; Stratton et al., 1989). In this mouse model, onco-
genic Kras is expressed from its endogenous promoter at phys-
iological levels (Tuveson et al., 2004). Second, tamoxifen
activates KrasG12D and Trp53 conditional mutations in an induc-
ible fashion via CreER in postnatal Pax7CE/+ andMyoDCE/+ mice.
Therefore, the initiating mutations are restricted to either Pax7+
(Lepper et al., 2009) or MyoD+ cells (Figures 2 and S2), so that
the consequences of transforming these cells can be studied
in vivo. Our results do not exclude more differentiated cells,
such as myotubes and myofibers, as potential cells of origin
for myogenic sarcomas. It is possible that initiating mutations
in myotubes or myofibers will also give rise to myogenic sar-
comas. This latter possibility will be explored in future studies us-
ing both Myogenin-CreER and Myf6-CreER mice.
In summary, we determined that Pax7+ myogenic progenitors
are a cell of origin for both UPS and RMS. We also found that
MyoD+ myogenic progenitors are a cell of origin for UPS. Taken
together, these results suggest that Pax7+MyoD quiescent sat-
ellite cells can be a cell of origin for RMS and that Pax7+MyoD+
cells can be a cell of origin for UPS, at least in the context of Kras
and Trp53 mutations. Finally, the two genetically engineered
mouse models for UPS and RMS reported here may be useful
for testing novel therapies for RMS and UPS in the preclinical
setting.
EXPERIMENTAL PROCEDURES
Mice and Sarcoma Generation
Mice were on a mixed 129 S4/SvJae and C57/Bl6 background. LSL-Kras
G12D
mice (Tuveson et al., 2004) were provided by T. Jacks (Massachusetts Institute
of Technology). Trp53Fl mice (Meuwissen et al., 2003) were obtained from
Anton Berns (The Netherlands Cancer Institute). The Pax7CE mice have been
previously described (Lepper et al., 2009), and the MyoDCE mice were gener-
ated as described in the Supplemental Experimental Procedures. R26mTmG
reporter mice were developed by Liqun Luo and obtained from The Jackson
Laboratory. Sarcomas were generated using intraperitoneal injections of
tamoxifen (Sigma-Aldrich) dissolved in EtOH and diluted in corn oil (10 ml
20 mg/ml tamoxifen per gram body weight). All animal experiments were per-
formed according to protocols approved by the Duke University Institutional
Animal Care and Use Committee.
Immunofluorescence and Immunohistochemistry
Tumor specimens were fixed in 10% formalin/70% EtOH and paraffin
embedded. Sections (4 mm) were stained with H&E or with antibodies (see
Supplemental Experimental Procedures). All IHCwas performed using Vectas-
tain Elite ABC Kit (mouse immunoglobulin G) and 3,30-diaminobenzidine tetra-
hydrochloride (Sigma-Aldrich). For immunofluorescence experiments, cells
were affixed to microscopy slides using a Shandon Cytospin 4 Cytocentrifuge
or grown on culture slides (BD Biosciences) and stained for the indicated pro-
tein. Immunofluorescence and immunohistochemistry images were captured
on a Leica DM5500B microscope using Leica Application Suite software.
Microarray Processing and Analysis
Gene expression of RMS and UPS was determined using Affymetrix 430A 2.0
arrays (Affymetrix). RNA was isolated using the RNeasy Fibrous Tissue Mini Kit
(Qiagen). The human data set was downloaded from GEO (GSE2553) (BairdCeet al., 2005). See the Supplemental Experimental Procedures for further
details.
ACCESSION NUMBERS
All microarray data have been deposited in the National Center for Biotech-
nology Information Gene Expression Omnibus under accession number
GSE46836.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2013.10.020.
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